The Supreme Court of the US has ruled that the abortion pill mifepristone can continue to be prescribed remotely and ...

Khalil Asmar, VP of cardiometabolic health at Lilly UK & Ireland (l), and former England spin bowler Ashley Giles (r). Like ...

UK reimbursement authority NICE has recommended that the NHS in England can use AstraZeneca's Imfinzi as the first ...

Regeneron's bid to join the US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised after the FDA approved its Lynozyfic drug at a second attempt. Lynozyfic ...

Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its approved therapy for the sleep disorder narcolepsy. Lundbeck's ...

The UK life sciences raised £1.23 billion ($1.65 billion) in venture capital investment in the first half of 2025, putting it on course to at least match the 2024 total for the full year. That's the ...

Emboldened by strong data for its oral IL-23 inhibitor icotrokinra in psoriasis, Johnson & Johnson has said it will see if it can outperform its big-selling injectable therapy Stelara in a ...

Pfizer’s Mylotarg looks set for a return to the US market after FDA advisers recommended its use in acute myeloid leukaemia. The drug comes with a fascinating history, and in many ways was a precursor ...

Biogen has decided to advance its tau-targeting Alzheimer's disease drug diranersen (BIIB080) into a phase 3 trial programme, ...

BeOne Medicines' Beqalzi has been cleared for a form of lymphoma by the FDA, and the US regulator has also granted a second ...

Regenxbio is pitching at FDA approval next year for its Duchenne muscular dystrophy (DMD) gene therapy RGX-202, after ...

Healthcare in the UK is at an inflection point. To ensure the NHS remains fit for the future, the Government launched its 10-Year Health Plan for England last year, setting out strong ambitions around ...